Respon Radiasi dan Kesintasan Karsinoma Nasofaring Stadium Lanjut Lokal di Departemen Radioterapi Rumah Sakit Cipto Mangunkusumo Periode Januari 2007-Desember 2011

Abstract

Penelitian ini bertujuan untuk mengetahui respon radiasi, kesintasan hidup, dan faktor yang mungkin mempengaruhi dalam penanganan karsinoma nasofaring stadium lanjut lokal. Penelitian ini merupakan penelitian retrospektif deskriptif analitik terhadap 391 pasien karsinoma nasofaring stadium lanjut lokal yang berobat di Departemen Radioterapi RSCM periode Januari 2007-Desember 2011. Respon radiasi dianalisa menggunakan uji korelasi Spearman dan analisis kesintasan dihitung dengan kurva Kaplan Meier pada pasien yang memenuhi kriteria inklusi. Didapatkan 70.6% pasien adalah laki laki, median usia 45 (9-86) tahun, sebagian besar stadium IVB (32,7%) dengan tipe histopatologis WHO III paling dominan (82,4%). Kesintasan hidup 3 dan 5 tahun untuk masing-masing stadium IIB, III, IVA, IVB berturut-turut adalah 64,9%,

Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients

“…The most common clinical stage in our sample was IVA (53.98%). These results differ from an earlier study in Jakarta that showed the most common stage to be IVB (32.7%) [ 6 ]. Studies in Hong Kong by Lee et al and Turkey by Topkan et al have reported the most prevalent stage to be III (68.24% and 56.4%) [ 4 , 23 ].…”

“…The histopathological characteristics of patients in Indonesia are the same as those in China [ 4 ] (90% WHO type III), which is chemoradiosensitive, but differ in terms of survival. In this study, the three-year mortality rate was 40.14%, which is better than in earlier studies conducted in Jakarta [ 6 ] and Yogyakarta [ 5 ] at which time, the rates were 47.1% and 70%, respectively. A study in China revealed a mortality rate of 22% [ 4 ].…”

“…In this study, we lacked median survival data because observations were limited to three years only. Rahajeng et al [ 6 ] reported that the median survival of locally advanced stage NPC patients might be up to 4.6 years.…”

“…It is the sixth most common cause of cancer-associated death in Indonesia [ 1 – 3 ]. The three-year survival rate of locally advanced NPC patients in Indonesia is lower than that in other Asian countries [ 4 – 6 ]. A previous study found that in our country, many patients are younger than thirty years old and have high latent membrane protein (LMP1) expression [ 1 ].…”